Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Experience With Intraplaque Injection of Verapamil for Peyronie’s Disease

Levine, Laurence A., Goldman, Karen E., Greenfield, Jason M. · 2002 · Journal of Urology

Abstract

PURPOSE: We examined the use of intraplaque injection of verapamil for the treatment of Peyronie's disease through its effects on pain, curvature, indentation, sexual function and erectile capacity. MATERIALS AND METHODS: A total of 156 men underwent treatment with intraplaque verapamil injection. Patients were assessed objectively, during dynamic penile duplex ultrasound, as well as subjectively using a questionnaire before and after initiation of the treatment protocol. Patients were also stratified by duration of disease before therapy and into 1 of 3 Kelami classification groups based on pretreatment plaque size and severity of curvature. Differences before and after treatment and among the Kelami classification groups were assessed. RESULTS: Of the 140 patients who completed treatment 73 (60%) had an objectively measured decrease in curvature while 79 (62%) reported a subjective decrease in curvature during the followup interview. After treatment 111 (83%) men reported an increase in girth, 107 (80%) an increase in rigidity distal to the plaque and 92 (71%) an improvement in sexual function. Among each Kelami class curvature was objectively measured to decrease in 41%, 68% and 62% of patients in classes I, II and III, respectively. There was no significant difference in response based on duration of disease (60% improvement versus 61% improvement for disease duration of less or greater than 1 year in duration, respectively). Mean followup was 30.4 months (range 10 to 81) and there was no reported recurrence of penile deformity in those men with an initial posttreatment positive response. CONCLUSIONS: Verapamil injection of Peyronie's plaques appears to be a clinically effective treatment option for pain and curvature and can contribute to subjective improvement in sexual function and erectile capacity. The low incidence of complications indicates that this therapy is also clinically safe.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-5347(05)64691-5

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 25

  1. Levine, 1997, Treatment of Peyronie’s disease with intralesional verapamil injection, J Urol, 158, 1395, 10.1016/S0022-5347(01)64224-1 · DOI
  2. Carson, 1997, Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective?, Tech Urol, 3, 135
  3. Lasser, 1998, Intraplaque verapamil injection for treatment of Peyronie’s disease, J La State Med Soc, 150, 431
  4. Ahuja, 1999, A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease, J Androl, 20, 444, 10.1002/j.1939-4640.1999.tb02539.x · DOI
  5. Gelbard, 1993, Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study, J Urol, 149, 56, 10.1016/S0022-5347(17)35998-0 · DOI · Paper page
  6. Cipollone, 1998, [Betamethasone versus placebo in Peyronie’s disease.] Arch Ital Urol, 70, 165
  7. Montorsi, 2000, Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results, J Androl, 21, 85, 10.1002/j.1939-4640.2000.tb03279.x · DOI
  8. Levine, 1994, Intralesional verapamil injection for the treatment of Peyronie’s disease, J Urol, 151, 1522, 10.1016/S0022-5347(17)35291-6 · DOI · Paper page
  9. Lee, 1990, Calcium antagonists retard extracellular matrix production in connective tissue equivalent, J Surg Res, 49, 463, 10.1016/0022-4804(90)90197-A · DOI
  10. Doong, 1996, The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts, J Burn Care Rehabil, 17, 497, 10.1097/00004630-199611000-00005 · doi:10.1097/00004630-199611000-00005
  11. Roth, 1996, Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix, Proc Natl Acad Sci USA, 93, 5478, 10.1073/pnas.93.11.5478 · DOI · Paper page
  12. Kelami, 1983, Classification of congenital and acquired penile deviation, Urol Int, 38, 229, 10.1159/000280897 · DOI
  13. Levine, 1996, Penile vascular assessment using color duplex sonography in men with Peyronie’s disease, J Urol, 155, 1270, 10.1016/S0022-5347(01)66239-6 · DOI
  14. Rehman, 1998, Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study, Urology, 51, 620, 10.1016/S0090-4295(97)00700-0 · DOI · Paper page
  15. Arena, 1995, [Clinical effects of verapamil in the treatment of Peyronie’s disease], Acta Biomed Ateneo Parmense, 66, 269
  16. Williams, 1970, The natural history of Peyronie’s disease, J Urol, 103, 75, 10.1016/S0022-5347(17)61894-9 · DOI
  17. Gelbard, 1990, The natural history of Peyronie’s disease, J Urol, 144, 1376, 10.1016/S0022-5347(17)39746-X · DOI · Paper page
  18. Kadioglu, 2001, Lessons learned from 307 men with Peyronie’s disease, J Urol, 165, 202
  19. Stetler-Stevenson, 1996, Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix, Am J Pathol, 148, 1345
  20. Hirano, 1997, Electron microscopic study of the penile plaques and adjacent corpora cavernosa in Peyronie’s disease, Int J Urol, 4, 274, 10.1111/j.1442-2042.1997.tb00188.x · DOI
  21. El-Sakka, 1998, Histological and ultrastructural alterations in an animal model of Peyronie’s disease, Br J Urol, 81, 445, 10.1046/j.1464-410x.1998.00529.x · DOI
  22. Dietrich, 1979, Effects of the calcium antagonist verapamil on in vitro synthesis of skeletal collagen and noncollagen protein, Endocrinology, 105, 1168, 10.1210/endo-105-5-1168 · doi:10.1210/endo-105-5-1168
  23. Kelly, 1985, Pathways of protein secretion in eukaryotes, Science, 230, 25, 10.1126/science.2994224 · DOI · Paper page
  24. Lee, 1994, The response of burn scars to intralesional verapamil, Arch Surg, 129, 107, 10.1001/archsurg.1994.01420250119015 · doi:10.1001/archsurg.1994.01420250119015
  25. Anderson, 2000, Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents, Int J Impot Res, 12, S25, 10.1038/sj.ijir.3900558 · DOI

Cited by

See all 185

Metadata

Authors
Levine, L. A., Goldman, K. E., & Greenfield, J. M.
Venue
Journal of Urology
Published
2002-08
Volume
168
Issue
2
Pages
621-626
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2114453886
Cited by
185
References
1
FWCI
4.44
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Experience With Intraplaque Injection of Verapamil for Peyronie’s Disease. https://app.cochat.ai/papers/10.1016/s0022-5347(05)64691-5
The paper
Levine, L. A., Goldman, K. E., & Greenfield, J. M. (2002). Experience With Intraplaque Injection of Verapamil for Peyronie’s Disease. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)64691-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.